Category:
Active Pharmaceutical Ingredients
CAS NO:
955365-80-7
Standard:
In-house Standards,
Oncology Ovarian Cancer
Lambrolizumab (MK-1775) is a monoclonal antibody targeting PD-L1, developed for oncology. It functions by blocking the PD-1/PD-L1 pathway to restore T-cell activity. Note: MK-1775 is actually Alisertib, an Aurora kinase A inhibitor; Lambrolizumab is typically associated with MK-3475 or similar agents. No standard CAS exists for "Lambrolizumab" as it appears to be a non-existent or misnamed compound in current databases.
Strict adherence to GMP guidelines required for handling. Storage at -20°C or below in original packaging. Clinical use limited to approved indications only; off-label application requires regulatory oversight. Safety data sheets must be consulted prior to processing.